Formycon and its licensing partner Klinge Biopharma have jointly announced the commercial launch of FYB203, a biosimilar to Eylea 2mg (Regeneron) across the European Union.

The launch of the pre-filled syringe (PFS) presentations marketed under the brand names Ahzantive and Baiama officially began on May 15, 2026, in European markets including Germany, France, and Italy. According to the companies, the rollout will continue gradually across additional Central and Eastern European countries over the coming weeks and months through multiple commercialization partners.

“With the launch of Ahzantive and Baiama, we are reaching another important milestone in scaling our portfolio commercially,” said Nicola Mikulcik, Chief Business Officer of Formycon AG. “In line with our FYB4Growth strategy, we are positioning our biosimilar broadly across Europe’s diverse market landscape together with several strong licensing partners. This provides patients with severe retinal diseases with another safe, effective, and cost-efficient treatment option.”

The launch follows a March 2026 settlement and licensing agreement between Formycon, Regeneron, and Bayer Healthcare, which cleared the path for commercialization in Europe beginning May 15, 2026. Earlier, in October 2025, Formycon had secured the right to launch the biosimilar in the United States in the fourth quarter of 2026, or potentially earlier under certain conditions, through a separate agreement with Regeneron.

Ahzantive and Baiama are being introduced initially as pre-filled syringes. Formycon noted that vial presentations of Ahzantive and Baiama are expected to be introduced in selected European markets over the coming months.